Advances and challenges in the treatment of lung cancer

Li, Yuting; Yan, Bingshuo; He, Shiming

doi:10.1016/j.biopha.2023.115891

Cited by 32 publications

(11 citation statements)

References 240 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have proved that the increased expression of key molecules of EMT signaling pathway (e.g., TWIST1, MMPs) was often accompanied by the increase of immune cell infiltration abundance in tumor microenvironment in breast cancer, which contributed to the immune escape of tumor cells [27]. Furthermore, many studies have confirmed that in a variety of cancers, the process of EMT was often accompanied by desensitization of immunotherapy drugs [28][29][30]. Our study indicated that differentially expressed THY1 not only got involved in the process of EMT, but also significantly correlated with the immune infiltration levels in LUSC.…”

Section: Discussionmentioning

confidence: 99%

THY1 is a prognostic-related biomarker via mediating immune infiltration in lung squamous cell carcinoma (LUSC)

Yi,

Zang,

Gao

et al. 2024

Aging

View full text Add to dashboard Cite

Thymus cell antigen 1 (THY1) has been proven to play pivotal roles in many diseases. However, we do not fully understand its functional mechanism, especially in lung squamous cell carcinoma (LUSC). Here, we aimed to perform a comprehensive analysis to explore the expression and prognostic values of THY1 in LUSC using bioinformatic technology. Some online public databases (e.g., ONCOMINE, PrognoScan, TIMER, Kaplan-Meier plotter, STRING, LinkedOmics, and GEPIA) were used to explore the expression, prognostic significance, and potential molecular mechanism of THY1. The analysis indicated that THY1 was significantly up-regulated and closely correlated with poor prognosis in many malignant tumors, including LUSC. Further analysis revealed that over-expression of THY1 was significantly correlated with clinicopathological parameters (e.g., individual cancer stage, age, smoking habits, nodal metastasis status, and TP53 mutation status) in LUSC. The CpG islands methylation of THY1 was negatively correlated with THY1 mRNA expression in The Cancer Genome Atlas Program (TCGA). Further enrichment analysis of THY1 correlated genes revealed that they were mainly correlated with the formation of extracellular matrix (ECM), and got involved in the pathway of epithelial mesenchymal transition (EMT). Furthermore, differentially expressed THY1 was significantly correlated with immune cell infiltrations and poor prognosis in LUSC. In summary, bioinformatic analysis demonstrated that THY1 was significantly over-expressed and closely correlated with unfavorable prognosis in LUSC, which may apply as a promising diagnostic and therapeutic biomarker for LUSC in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

THY1 is a prognostic-related biomarker via mediating immune infiltration in lung squamous cell carcinoma (LUSC)

Yi,

Zang,

Gao

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…However, vast tumor heterogeneity and acquired drug resistance limit the efficacy of targeted therapy as well. In this context, the identification of agents that can specifically target molecular pathways that are frequently dysregulated in lung cancer is crucial for improving the clinical outcomes of patients [105,106]. Alterations in different components of the PI3K/Akt/mTOR pathway, including somatic mutations of PIK3CA, deletions of PTEN, and increased Akt activity, have been recorded in most NSCLC cases, resulting in this pathway being one of the most frequently deregulated in lung cancer [107][108][109].…”

Section: Lung Cancermentioning

confidence: 99%

The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway

Zoi,

Kyritsis,

Galani

et al. 2024

Cancers

View full text Add to dashboard Cite

Cancer is a life-threatening disease and one of the leading causes of death worldwide. Despite significant advancements in therapeutic options, most available anti-cancer agents have limited efficacy. In this context, natural compounds with diverse chemical structures have been investigated for their multimodal anti-cancer properties. Curcumin is a polyphenol isolated from the rhizomes of Curcuma longa and has been widely studied for its anti-inflammatory, anti-oxidant, and anti-cancer effects. Curcumin acts on the regulation of different aspects of cancer development, including initiation, metastasis, angiogenesis, and progression. The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway is a key target in cancer therapy, since it is implicated in initiation, proliferation, and cancer cell survival. Curcumin has been found to inhibit the PI3K/Akt pathway in tumor cells, primarily via the regulation of different key mediators, including growth factors, protein kinases, and cytokines. This review presents the therapeutic potential of curcumin in different malignancies, such as glioblastoma, prostate and breast cancer, and head and neck cancers, through the targeting of the PI3K/Akt signaling pathway.

show abstract

“…In contrast, as the disease progresses to stage III or IV, the therapeutic decision transitions toward chemotherapy or radiotherapy. Nevertheless, conventional chemotherapeutic agents exhibit some limitations, comprising low bioavailability, non-specific targeting, and the emergence of drug resistance [ 4 ]. Taken together, the development of innovative cancer treatments is crucial for improving survival rates, overcoming the adverse effects of current therapies, and mitigating challenges associated with tumor drug resistance [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Natural Products Derived from Marine Sponges with Antitumor Potential against Lung Cancer: A Systematic Review

Ortigosa-Palomo,

Quiñonero,

Ortiz

et al. 2024

Marine Drugs

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC), the most commonly diagnosed cancer and the leading cause of cancer-related death worldwide, has been extensively investigated in the last decade in terms of developing new therapeutic options that increase patient survival. In this context, marine animals are a source of new, interesting bioactive molecules that have been applied to the treatment of different types of cancer. Many efforts have been made to search for new therapeutic strategies to improve the prognosis of lung cancer patients, including new bioactive compounds and cytotoxic drugs from marine sponges. Their antitumoral effect can be explained by several cellular and molecular mechanisms, such as modulation of the cell cycle or induction of apoptosis. Thus, this systematic review aims to summarize the bioactive compounds derived from marine sponges and the mechanisms by which they show antitumor effects against lung cancer, exploring their limitations and the challenges associated with their discovery. The search process was performed in three databases (PubMed, SCOPUS, and Web of Science), yielding a total of 105 articles identified in the last 10 years, and after a screening process, 33 articles were included in this systematic review. The results showed that these natural sponge-derived compounds are a valuable source of inspiration for the development of new drugs. However, more research in this field is needed for the translation of these novel compounds to the clinic.

show abstract

Advances and challenges in the treatment of lung cancer

Cited by 32 publications

References 240 publications

THY1 is a prognostic-related biomarker via mediating immune infiltration in lung squamous cell carcinoma (LUSC)

THY1 is a prognostic-related biomarker via mediating immune infiltration in lung squamous cell carcinoma (LUSC)

The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway

Natural Products Derived from Marine Sponges with Antitumor Potential against Lung Cancer: A Systematic Review

Contact Info

Product

Resources

About